Myovant’s uterine fibroid drug meets goals in trial, setting up competition with AbbVie. (STAT Plus)

More reads

• It may be time to revoke approval of Acadia Pharma’s anti-psychosis drug. (STAT Plus)
• Study: Higher cost of new cholesterol drugs putting patients at risk. (HealthDay)
• Merck unveils early data on HIV drug it says could be ‘a game changer.' (STAT)
• Myovant’s uterine fibroid drug meets goals in trial, setting up competition with AbbVie. (STAT Plus)